Strategic Alliance for cancer disease

Farmalider and Curaxys create a Technological and Commercial Strategic Alliance leading I+D of generic and biogeneric compounds for cancer disease

The pharmaceutical companies, Farmalider and Curaxys, have signed an important I+D and commercial agreement where Farmalider transfers an important portfolio of generic and biogeneric products and will also participate in the I+D of the biosimilar products of Curaxys. The first product to be developed is a MAB for cancer treatment. Both companies will collaborate together for the creation of the protein injectable plant, vaccine and anticancerous with a production capacity of 20.000.000 units per year.



El Puerto de Santa María. 12/07/2011. Curaxys, biopharmaceutical SME located in the Parque Tecnológico de Tecnobahia in Cádiz, Spain, is dedicated to I+D, production and commercialisation of generic and biogeneric medicaments with Farmalider.

Farmalider is a pharmaceutical company located in Madrid characterised in the generic development with equivalent formulas found in the market and others more innovative as Onedose®. Likewise, Farmalider is developing over 20 added values and innovative therapeutic products. Farmalider is working in the Patent elaboration and with the designs of the efficiency clinics and recently has obtained a Pharmaceutical Production Plant. Farmalider was created 25 years ago in the Pharmaceutical sector and is starting to be known as an “Idea Factory”.

The agreement between Farmalider and Curaxys began its activity as a leader in generic and biogeneric field and will obtain, in the coming years, around 40 products in the market achieving:

Strong presence in generic field for the transfer and Curaxys purchase of this important generic medicine packet of the Spanish market.
Take advantage of the Know-How of Farmalider in Pharmaceutical Technology for working in vectors and new pharmaceutical formulas to be used as a vehicle for the Biosimilar products, vaccine and of the Oncologic of the new plant.

Curaxys is specialised in the commercialisation of generic medicaments and biosimilar production and commercialisation

Curaxys technology is characterised for the capacity of cellular modification for production of MAB, protein recombinant and vaccine. Farmalider will invest in pharmaceutical formulation and the regulatory development of the biological medicament for the “Agencia del Medicamento” (Medicament Agency) approval.

This business initiative is the pioneer, known in Spain, where it is invested, developed, produced and commercialised this kind of product with own technology. Curaxys will develop this industrial project in two phases:

  • Phase I: already started with the construction of the biopharmaceutical plant which will was finalised in September 2012
  • Phase II: started in the first quarter of 2012 with the construction of injectable production factory with pharmaceutical technology developed by Farmalider and with a production capacity of 20 million units per year for cancer treatment which will be finished in the first quarter of 2014

This business initiative supports and validates the aim of obtaining a cheaper “Public Health System” with a fair price. This biosimilar medicament development project has been approved by different initiatives supported by the Ministerio de Ciencia e Innovacion ( Spanish General Office of Science and Innovation) through different programmes; INNCORPORA 2010 and Torres Quevedo 2010, the Ministerio de Industria (Spanish General Office of Industry) through Reindustrialización 2010 and 2011 of Cádiz Bay, the “Junta de Andalucía” for the creation of a high tech company, the Mininisterio de Economía y Hacienda (Spanish General Office of Economy and Treasure) through “Incentivos Regionales”, and the CDTI of the Ministerio de Industria and the initiative of the Plan Bahía Competitiva of Cádiz of the Agencia IDEA.

For further information please contact:
Paula Esteban del Río.
Communication and Marketing Department
Móvil: +34 609 834 996

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

More articles

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice